A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes
Clinical trial NCT05298254 · COMPLETED
Trial details
- NCT number
- NCT05298254
- Sponsor
- GlaxoSmithKline
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-07
- Primary completion
- 2025-06-12
- Enrollment
- 505
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.